Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04892212
Other study ID # HS-2743
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date June 30, 2021
Est. completion date October 30, 2023

Study information

Verified date May 2021
Source Peking Union Medical College Hospital
Contact Chao Li, MD
Phone 86-010-69155058
Email superchad099@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week follow-up. Primary Objective: - To investigate the efficacy of sirolimus for mild proteinuric flares in patients with Class III/IV±V lupus nephritis Secondary Objective: - To assess the safety and tolerability of sirolimus treatment for mild proteinuric flares in patients with Class III/IV±V lupus nephritis


Description:

Lupus nephritis is a common and serious complication of systemic lupus erythematosus (SLE). It often requires aggressive immunosuppressive therapy. Although majority of patients with severe lupus nephritis achieve a complete or partial remission after 6-month induction treatment, renal flares can still occur during maintenance therapy. Whether patients with mild proteinuric flares should receive intensive immunosuppressive therapy is unclear. In pathogenesis of SLE, T-cell dysfunction is attributed to the activation of the mammalian target of rapamycin (mTOR). Previous prospective and retrospective studies in SLE or lupus nephritis showed the effect of mTOR blockade on systemic disease activity index or severe lupus nephritis as initial or maintenance therapy. Eligible subjects with biopsy-proven Class III/IV±V lupus nephritis(ISN/RPS 2003) are received oral sirolimus without change previous immunosuppressive therapy. We follow up the included patients at Week 2, Week 4, Week6, Week 8 and Week 12 regularly. The investigator will actively detect and inquire about the occurrence of adverse events (AEs)/ severe adverse events (SAEs) at every visit/ contact during the study. The clinical trials insurance is prepaid by sponsor to cover the design risks of the protocol and liability/ compensation to the research subject for bodily injury or death resulting from their participation in the trial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Biopsy-proven Class III or IV±V lupus nephritis (ISN/RPS 2003 lupus nephritis classification) with biopsy performed within 48 weeks before inclusion. - Males or females aged 18 to 60 years old at the time of screening. - The mild proteinuric flare of lupus nephritis is defined as meeting all of the following criteria : 1. Persistently increased proteinuria after complete remission, and 24-hr proteinuria=1.0g/day or doubling of proteinuria after partial remission, and 24-hr proteinuria=2.0g/day 2. No hypoalbuminemia: serum albumin =35g/L 3. Stable renal function: serum creatinine<25% increase above the level at the time of renal disease remission - Eligible to sign informed-consent independently Exclusion Criteria: - Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial diseases, renovascular disease), or transplanted kidney - Estimate glomerular filtration rate (eGFR by CKD-EPI)<45mL/min per 1.73m^2 at the time of screening - Renal biopsy showing cellular of fibrocellular crescent in more than 25% of glomeruli - Central nervous system (CNS) or other severe organ manifestations of lupus that necessitate aggressive immunosuppressive therapy on its own. - Co-morbidities that require corticosteroid therapy (e.g. asthma, inflammatory bowel disease) - Any increased dose of corticosteroids or other immunosuppressive medication including cyclophosphamide, mycophenolate, leflunomide, calcineurin inhibitors, azathioprine, methotrexate, or use of biological agents regardless of duration, with the past six months - Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection history: seropositivity of HBV surface antigen (HBsAg) or HCV antibodies (HCV-Ab) - Women who are pregnant or breastfeeding - Women with childbearing potential or their male partners, who refuse to use an effective birth control method

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sirolimus
The daily dose of sirolimus is divided twice.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Peking Union Medical College Hospital North China Pharmaceutical Group Corporation

References & Publications (5)

Eriksson P, Wallin P, Sjöwall C. Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. Front Pharmacol. 2019 Feb 6;10:82. doi: 10.3389/fphar.2019.00082. eCollection 2019. — View Citation

Esatoglu SN, Seyahi E. Is sirolimus a treatment option for patients with systemic lupus erythematosus? Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 122(6):13. Epub 2019 Jul 12. — View Citation

Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018 Mar 24;391(10126):1186-1196. doi: 10.1016/S0140-6736(18)30485-9. Epub 2018 Mar 15. — View Citation

Ma MKM, Yung S, Chan TM. mTOR Inhibition and Kidney Diseases. Transplantation. 2018 Feb;102(2S Suppl 1):S32-S40. doi: 10.1097/TP.0000000000001729. Review. — View Citation

Yap DYH, Tang C, Chan GCW, Kwan LPY, Ma MKM, Mok MMY, Chan TM. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. J Rheumatol. 2018 Dec;45(12):1663-1670. doi: 10.3899/jrheum.180507. Epub 2018 Oct 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The number of patients achieving sustained Renal Response(RR) Sustained RR is defined as satisfying all of the following criteria:
1)Proteinuria is improved by =50% compared with baseline
2)24-hr urine protein < 1g
3)Serum creatinine is not higher than 15% above baseline level
4)No occurrence of non-renal disease flare after achieving response to treatment.
at the end of 12 weeks (3 months) from baseline
Secondary Complete renal remission 24-hr urine protein<0.3g/day or urine Protein-Creatinine ratio (uPCR)<300mg/g
Serum creatinine not higher than 15% above baseline level
at the end of 12 weeks (3 months) from baseline
Secondary Partial renal remission 24-hr urine protein<3.5g/day or uPCR<3500mg/g
Serum creatinine not higher than 15% above baseline level
at the end of 12 weeks (3 months) from baseline
Secondary Rate of non-renal flare Central nervous system or other severe organ manifestations of SLE that necessitate aggressive immunosuppressive therapy on its own during the 3-month follow up
Secondary Safety and tolerability of study medications The following parameters will be monitored:
Increase of serum creatinine level>15% from baseline and whether it is reversible or irreversible
Episodes with sirolimus level above the target range
New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication
Infectious requiring hospitalization and the causative agents
Hospitalization episodes- cause, duration (days)
Hypokalemia: serum potassium <3.5mmol/L
Metabolic acidosis with HCO3 <17mmol/L
New-onset hypercholesterolemia present at 3 months or beyond from baseline and/or addition of lipid-lowering drug(s).
Premature discontinuation from the study due to treating intolerance
Premature discontinuation from the study due to rapid disease progression or other reasons
Failure to adhere to the protocol defined corticosteroid reduction regimen
Other adverse clinical events or events considered clinically significant
during the 3-month follow up
Secondary Increase of serum creatinine level>15% from baseline Increase of serum creatinine level (µmol/L)>15% from baseline and whether it is reversible or irreversible. during the 3-month follow up
Secondary Episodes with sirolimus level above the target range Episodes with sirolimus level above the target range(serum sirolimus trough level>8ng/mL) will be recorded. during the 3-month follow up
Secondary New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication Hypertension be diagnosed when a person's systolic blood pressure (SBP) in the office or clinic is =140 mm Hg and/or their diastolic blood pressure (DBP) is =90 mm Hg following repeated examination.
New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication will be recorded.
during the 3-month follow up
Secondary Infection requiring hospitalization Infection requiring hospitalization will be recorded including the site of infection, the causative agent and duration (days). during the 3-month follow up
Secondary Hypokalemia Serum potassium <3.5mmol/L during the 3-month follow up
Secondary Hypercholesterolemia New-onset hypercholesterolemia present during follow-up or beyond from baseline and/or addition of lipid-lowering drug(s) during the 3-month follow up
Secondary Premature discontinuation from the study The time of of discontinuation from study will be recorded, and the discontinuation is due to:
treating intolerance
rapid disease progression
other reasons
during the 3-month follow up
Secondary Failure to adhere to the protocol Failure to adhere to the protocol including:
do not titer the dose of sirolimus following study protocol
increase the dose of other immunosuppressives personally without the permission of physician
during the 3-month follow up
Secondary Changes in Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) assesses disease activity by scoring 24 weighted disease activity descriptors of SLE as "present" or "absent" in preceding 10 days. A patient's total score is the sum of all marked SLE-related descriptors; a total score ranges between 0 and 105, with a higher score representing a more significant degree of disease activity.
Assessment scales of SELENA-SLEDAI is available online.
from baseline to end of 12 weeks
Secondary Changes in Physician Global Assessement (PGA) The Physician Global Assessment (PGA) is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks. Mild flare will score 1.0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale. PGA is available online. from baseline to end of 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Completed NCT03610516 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Active, not recruiting NCT05704088 - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A